BOSTON SCIENTIFIC CORPORATION Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net
BOSTON SCIENTIFIC CORPORATION (BSX) reported Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net of $8.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnCashFlowHedgeIneffectivenessNet · last filed 2023-02-23
- BOSTON SCIENTIFIC CORPORATION gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2020-12-31 was -$1.00M.
- BOSTON SCIENTIFIC CORPORATION gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2020-09-30 was -$2.00M.
- BOSTON SCIENTIFIC CORPORATION gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2020-06-30 was -$1.00M.
- BOSTON SCIENTIFIC CORPORATION gain (loss) on cash flow hedge ineffectiveness, net for the quarter ending 2020-03-31 was $33.00M.
- BOSTON SCIENTIFIC CORPORATION gain (loss) on cash flow hedge ineffectiveness, net for fiscal 2022 was $8.00M, a 66.67% decline from fiscal 2021.
- BOSTON SCIENTIFIC CORPORATION gain (loss) on cash flow hedge ineffectiveness, net for fiscal 2021 was $24.00M, a 17.24% decline from fiscal 2020.
- BOSTON SCIENTIFIC CORPORATION gain (loss) on cash flow hedge ineffectiveness, net for fiscal 2020 was $29.00M, a 14.71% decline from fiscal 2019.
- BOSTON SCIENTIFIC CORPORATION gain (loss) on cash flow hedge ineffectiveness, net for fiscal 2019 was $34.00M, a 385.71% increase from fiscal 2018.
| Period end | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 3 month | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 6 month | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 9 month | Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net 12 month |
|---|---|---|---|---|
| 2022-12-31 | $8.00M 10-K · filed 2023-02-23 | |||
| 2021-12-31 | $24.00M 10-K · filed 2023-02-23 | |||
| 2020-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$3.00M derived: sum of 2 quarters · filed 2022-02-23 | -$4.00M derived: sum of 3 quarters · filed 2022-02-23 | $29.00M 10-K · filed 2022-02-23 |
| 2020-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$3.00M derived: sum of 2 quarters · filed 2020-11-05 | $30.00M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $32.00M 10-Q · filed 2020-08-05 | ||
| 2020-03-31 | $33.00M 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $34.00M 10-K · filed 2021-02-23 | |||
| 2018-12-31 | $7.00M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |